Stem Cell Clinic

Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 – The InvestChronicle

By Embryonic Stem Cells

Lets start up with the current stock price of AgeX Therapeutics Inc. (AGE), which is $1.26 to be very precise. The Stock rose vividly during the last session to $1.40 after opening rate of $0.99 while the lowest price it went was recorded $0.94 before closing at $0.96.

Recently in News on June 16, 2020, AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications. AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeXs research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs. You can read further details here

AgeX Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.2400 on 01/02/20, with the lowest value was $0.6660 for the same time period, recorded on 04/21/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, AgeX Therapeutics Inc. shares are logging -59.87% during the 52-week period from high price, and 89.19% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.67 and $3.14.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2356457 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AgeX Therapeutics Inc. (AGE) recorded performance in the market was -30.77%, having the revenues showcasing 59.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 50.56M, as it employees total of 17 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8843, with a change in the price was noted +0.1000. In a similar fashion, AgeX Therapeutics Inc. posted a movement of +8.62% for the period of last 100 days, recording 309,646 in trading volumes.

Raw Stochastic average of AgeX Therapeutics Inc. in the period of last 50 days is set at 45.74%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 77.27%. In the last 20 days, the companys Stochastic %K was 68.95% and its Stochastic %D was recorded 58.59%.

Considering, the past performance of AgeX Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -30.77%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -31.89%, alongside a downfall of -55.16% for the period of the last 12 months. The shares increased approximately by 37.45% in the 7-day charts and went down by 55.12% in the period of the last 30 days. Common stock shares were driven by 59.01% during last recorded quarter.

The rest is here:
Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 - The InvestChronicle

Why are scientists trying to manufacture organs in space? – Stuff Magazines

By Embryonic Stem Cells

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that ispolarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

Read this article:
Why are scientists trying to manufacture organs in space? - Stuff Magazines

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -…

By Platelet Rich Plasma Injections

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/24200

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Orange County Hair Restoration Center

Colorado Surgical Center&, Hair Institute

Evolution Hair Loss Institute

Hair Sciences Center of Colorado

Hair Transplant Institute of Miami

Anderson Center for Hair

Virginia Surgical Center

Savola Aesthetic Dermatology Center

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Platelet Rich Plasma Injections

Stem Cell Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies for each application, including

Dermatology Clinics

Hospitals

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/24200

Major Point of TOC:

Chapter One: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

Chapter Two: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Player

Chapter Three: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Type

Chapter Four: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Application

Chapter Five: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Sales Channel

Chapter Six: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Region

Chapter Seven: Profile of Leading Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players

Chapter Eight: Upstream and Downstream Analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Chapter Nine: Development Trend of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/24200

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

See the article here:
What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -...

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – Tyler Morning Telegraph

By Stem Cell Medicine

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Here is the original post:
COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - Tyler Morning Telegraph

Growing Demand for Anti Aging Medicine Market to Significantly Increase Revenues Through 2026 – 3rd Watch News

By Stem Cell Medicine

Longer life-expectancy is a cumulative effect of a healthy lifestyle and favorable environmental conditions. A trend of continuously increasing life expectancy has been a witness since a decade, primarily because of advances in medical sciences and treatment of chronic life-threatening diseases, availability of clean water and environment and other factors. This trend is projected to further show even more exponential growth graph owing to the anti-aging medicines, stem cell therapeutics, genetic screening and interventions, and high-tech biomedicines.

American Academy of Anti-Aging Medicine claimed that anti-aging medicines can add up to 10-20 years to the life expectancy of a human. Today, a combination of calorie-restricted diet, regular exercise, and anti-aging medicines are claimed to slow the process of senescence and aging. Various medicines used against the treatment of acute or chronic diseases can be considered as anti-aging medicines, however, to define anti-aging medicine market we have considered only the drugs that are directly prescribed and used for delaying the effects of aging.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/26233

The constantly growing demand to look young in old individuals and to remain young and youthful in young people drive the anti-aging market. The influence of aesthetics from the fashion and television industry propel the demand to retain the features and energy of younger age in old people. Additionally, the increasing number of anti-aging medicine manufacturers in the decade contribute to higher availability of the anti-aging medicine resulting in expansion of the global anti-aging medicine market. However, skeptical approach to anti-aging medicine as being an external stimulator of cell-cycles is a restraint to the expansion of anti-aging medicine market.

The global Anti-aging medicine market is segmented on basis of product type, age group, distribution channel, and region:

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/26233

The rising demand for beauty consciousness amongst people and the desire to stay young is the primary factor fueling the growth of anti-aging medicines in the market. The acclaimed benefits of the products and affordability along with regional presence compel the demand for anti-aging medicine in the global market. Hormonal replacement therapy segment in product type is expected to account maximum market share in the terms of revenue in the global anti-aging medicine market. However, antioxidant therapy segment in product type is expected to grow with the highest CAGR over the forecast years owing to the rising awareness about the plethora of benefits of antioxidants in anti-aging among the public. On the basis of the route of administration, the global anti-aging medicine market is segmented as oral, injectable and topical, out of which oral segment is expected to generate maximum revenue share over the forecast period. As per the distribution channel, the global anti-aging medicine market is segmented as hospital pharmacies, retail pharmacies, e-commerce, and drug stores. The e-commerce segment in the distribution channel is estimated to grow with the highest CAGR over the forecast time.

Regionally, the global anti-aging medicine market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America anti-aging medicine market is projected to account for the largest market share in the terms of revenue in the global anti-aging medicine market owing to the higher healthcare expenditure and presence of numerous manufacturers. Europe is expected to hold the second largest share in the global anti-aging medicine market during the forecast period because of the growing geriatric population and higher spending on healthcare products and supplements. MEA anti-aging medicine market is expected to witness sluggish growth over the forecast time owing to the limited presence of manufacturers and lower healthcare expenditure. Asia Pacific is projected to grow with the highest CAGR over the forecast years in the global anti-aging medicine market due to higher demand from end users and regional penetration of the key players in the region.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/26233

Some of the players operating in the global anti-aging medicine market are

Originally posted here:
Growing Demand for Anti Aging Medicine Market to Significantly Increase Revenues Through 2026 - 3rd Watch News

COVID-19 Impact on Regenerative Medicine Market 2020: Global Industry Size, Growth, Emerging Trends, Business Opportunities, SWOT Analysis by Top Key…

By Stem Cell Medicine

The report provides 360 analysis ofRegenerative Medicine Marketfrom view of manufacturers, regions, product types and end industries.

The research report analyses and provides the historical data along with current performance of the global Regenerative Medicine industry, and estimates the future trend of Regenerative Medicine market on the basis of this detailed study.

Get Sample Copy @https://www.orianresearch.com/request-sample/574056

Reasons for Buying this Report: This report provides pin-point analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

The report covers projection as well as evaluation for the Regenerative Medicine market on a global as well as regional level. The study offers Regenerative Medicine historic information of 2017 in addition to a forecast from 2018 to 2025 based upon both quantity (Million Units) as well as revenue (USD Million).

The research study includes chauffeurs and restraints for the Regenerative Medicine market along with the influence they carry the demand over the projection period. Additionally, the record includes the research of opportunities offered in the Regenerative Medicine market on a global level.

Complete report on Regenerative Medicine Market report spread across 152 pages, profiling 20 companies and supported with tables and figures available, Do Inquire more if any on this report @https://www.orianresearch.com/enquiry-before-buying/574056

Moreover, the report also offers key insights on the latest developments in the Regenerative Medicine Market that are transforming global industry. The report on the global Regenerative Medicine Market shows how the market performed in past and how it is expected to perform in the next few years.

The global Regenerative Medicine market is valued at 5350 million USD in 2017 and is expected to reach 19000 million USD by the end of 2025, growing at a CAGR of 23.5% between 2017 and 2025.

USA is the largest market of regenerative medicine, which occupies 51.09 percent of global regenerative medicine market share in 2015. It is followed by EU, which has around 16.66 percent of the global total industry. Other main regions which take important part in this industry include Japan and China.

Dominant Regenerative Medicine Market TOP Players: Competitive Insights

DePuy Synthes Medtronic ZimmerBiomet Stryker Acelity MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologies Bellicum Pharmaceuticals

Global Regenerative Medicine Market report also includes Regenerative Medicine Market Business Overview. It also includes Regenerative Medicine Market by Applications and Type, Regenerative Medicine Revenue, Sales and Price and Regenerative Medicine Business Share. This report of Regenerative Medicine Market research also consists Global Regenerative Medicine Market Competition, by Regenerative Medicine market revenue of regions, sales and by Regenerative Medicine industry Competitive Players like.(2013-2018)

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/574056

Global Regenerative Medicine Market: Type Outlook:

Cell Therapy Tissue Engineering Biomaterial Other

Global Regenerative Medicine Market: Application Outlook:

Dermatology Cardiovascular CNS Orthopedic Others

Global Regenerative Medicine Market: Regional Outlook:

Europe Regenerative Medicine Market(Germany, France, Italy, Russia and UK)

North America Regenerative Medicine Market (Canada, USA and Mexico) Latin America Regenerative Medicine Market (Middle and Africa). Regenerative Medicine Market in Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Asia-Pacific Regenerative Medicine Market (South-east Asia, China, India, Korea and Japan).

Report on (2018-2025 Regenerative Medicine Market Report) mainly covers 15 sections acutely display the global Regenerative Medicine market:

Chapter 1: Describe Regenerative Medicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Chapter 2: Analyze the top manufacturers of Regenerative Medicine, with sales, revenue, and price of Regenerative Medicine, in 2016 and 2017; Chapter 3: Display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4: Show the global market by regions, with sales, revenue and market share of Regenerative Medicine, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9: Analyze and talked about the key regions, with sales, revenue and market share by key countries in these regions. Chapter 10 and 11: Show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12: In Chapter Eleven Regenerative Medicine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2025; Chapter 13, 14 and 15: Describe Regenerative Medicine sales channel, distributors, traders, dealers, appendix and data source.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez Vice President Global Sales & Partner Relations Orian Research Consultants US: +1 (832) 380-8827 | UK: +44 0161-818-8027 Email:[emailprotected] Website: http://www.orianresearch.com/

See the rest here:
COVID-19 Impact on Regenerative Medicine Market 2020: Global Industry Size, Growth, Emerging Trends, Business Opportunities, SWOT Analysis by Top Key...

Short Read Sequencing Market Share Analysis to 2027 | GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI – Cole of Duty

By Gene Therapy Clinics

Global Short Read Sequencing MarketBy Technology (Next- Generation Sequencing, Sanger Sequencing), Product (Instruments, Consumables, Services), Application (Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics), Workflow (Pre- Sequencing, Sequencing, Data Analysis), End- User (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Trends and Forecast to 2027

Global Short Read Sequencing Marketresearch report is very much essential in many ways to grow the business and thrive in the market. The market transformations are highlighted here which occur because of the moves of key players and brands like developments, product launches, joint ventures, merges and accusations that in turn changes the view of the global face ofHealthcareindustry.

Request For Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-short-read-sequencing-market

The major players covered in the short read sequencing market report are Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Illumina, Inc, GENEWIZ, GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI, Fasteris, General Electric, Eurofins Scientific, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Cell and Gene Therapy Digital Conference| Register at:https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Market Analysis and Insights:Global Short Read Sequencing Market

Short read sequencing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 23.15 billion by 2027 growing at a CAGR of 11.34% in the above-mentioned forecast period. Increasing demand for personalized medicines and technological advancement & development in healthcare industry are the factor for the growth of this market.

Increasing adoption of short-read sequencing is the factor for the growth of this market. There is also increasing collaboration & partnership for genetic sequencing which is also expected to drive the market. They are also cost- effective method of detection of genetic abnormalities which also enhance the market growth. Rising demand for advanced technologies for clinical diagnostics is another factor which is also expected to create opportunities for the short read sequencing market in the forecast period of 2020- 2027

This short read sequencing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Briefour team will help you create a revenue impact solution to achieve your desired goal.

Global Short Read Sequencing Market Scope and Market Size

Short read sequencing market is segmented of the basis of technology, application, product, workflow, and end- users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on technology, short read sequencing market is segmented into next- generation sequencing, and sanger sequencing.

Short read sequencing market is segmented on the basis of product are instruments, consumables, and services.

On the basis of application, the short read sequencing market is segmented on the basis of oncology, clinical investigation, reproductive health, HLA typing/immune system monitoring, metagenomics, epidemiology & drug development, agrigenomics & forensics, and consumer genomics.

The workflow segment is further divided into pre- sequencing, sequencing, and data analysis.

The global short read sequencing market has also been segmented based on the end use into academic research, clinical research, hospitals & clinics, pharma & biotech entities, and other.

For More Details In-Depth Inquiry @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-short-read-sequencing-market

Short Read Sequencing Market Country Level Analysis

Short read sequencing market is analysed and market size insights and trends are provided by country, technology, application, product, workflow, and end- users as referenced above.

The countries covered in the short read sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the digital short read sequencing market due to availability of a regulatory environment supporting the development of genomics while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 because of changing reimbursement policy in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Short read sequencing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for short read sequencing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the short read sequencing market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Short Read Sequencing Market Share Analysis

Short read sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to digital short read sequencing market.

Customization Available:Global Short Read Sequencing Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

View Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-short-read-sequencing-market

View post:
Short Read Sequencing Market Share Analysis to 2027 | GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI - Cole of Duty

Homology Medicines Appoints Jeff Poulton to the Board of Directors – GlobeNewswire

By Stem Cell Clinic

July 21, 2020 08:00 ET | Source: Homology Medicines, Inc.

- Executive with Extensive Rare Disease Expertise in Global Finance andCommercial Operations -

BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors. Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homologys Board of Directors, including leading finance, business development and commercial operations at companies using differentiated technologies to develop treatments for patients with rare diseases.

I had the pleasure of working with Jeff before, and I know first-hand how his strategic financial and operational leadership contributed to the success of a global rare disease commercial business, said Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. Jeff has also displayed a long-term commitment to help patients and their families, which aligns with Homologys mission to develop our gene therapy and nuclease-free gene editing platform into new treatments and potential cures. He joins at an important time in the development of our pipeline, and we look forward to his guidance as we progress our Phase 1/2 pheNIX gene therapy clinical trial for adults with PKU and work toward bringing our other development candidates to the clinic.

Prior to his role at Alnylam, Mr. Poulton served as CFO at Indigo Agriculture where he supported the initial commercial scale-up of the business, including expansion outside the US. Mr. Poulton previously held various roles of increasing responsibility at Shire Plc, concluding his service as CFO and a member of its Executive Committee and Board of Directors. During his tenure at Shire, Mr. Poulton led the rare disease commercial operations in the US, Latin America, and Asia Pacific, as well as its global rare disease business unit. Prior to Shire, he led corporate finance and business development initiatives in both the energy and materials manufacturing sectors in financial leadership positions at Cinergy Corp and PPG industries. He also served in the US Navy as a Commissioned Officer. Mr. Poulton has an MBA in Finance from the Kelley School of Business at Indiana University and a bachelors degree in Economics from Duke University. He also serves as a member of the Board of Directors at EIP Pharmaceuticals.

I am drawn to companies with transformative technologies, and I believe Homologys genetic medicines platform has the potential to change the lives of patients with rare diseases, said Mr. Poulton. I look forward to working with the team at Homology, many of whom have successful careers in developing and commercializing drugs at prior companies that are continuing to make a positive impact in the lives of patients and families living with rare diseases.

About Homology Medicines, Inc. Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homologys proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicinesin vivoeither through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visitwww.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our genetic medicines platform; the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; and our position as a leader in the development of genetic medicines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities and potential expansion of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and our other filings with theSECcould cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Original post:
Homology Medicines Appoints Jeff Poulton to the Board of Directors - GlobeNewswire

Higher Steaks Creates World’s First Lab-Grown Bacon and Pork Belly – The Spoon

By Adult Stem Cells

United Kingdom based startup Higher Steaks announced today they have successfully created the worlds first lab-grown prototypes for bacon and pork belly.

The production of the first cultivated bacon is big news for those excited for alternatives to industrially produced meat. While 2020 has been a big year for alt-pork, with Impossible launching their plant-based pork at CES and Omnipork debuting their plant-based pork shoulder, this news from Higher Steaks marks the first time bacon and pork belly has been developed from actual animal cells.

The interest in alt-pork shouldnt be surprising since the meat from pigs is the most consumed type of meat in the world. However, countries like China have seen huge viral threats to their pig population, with around half being wiped out in 2019 due to Swine Fever.

According to company CEO Benjamina Bollag, the protoypes took approximately one month to create, developed from a type of a highly adaptable type of stem cell called induced pluripotent stem cells.

In nature, you have adult stem cells and embryonic stem cells, Bollag told The Spoon in an interview. And this is a way of taking any cell in the body and bringing it back to the embryonic state. Which means that you can expand those cells a lot more and you can make any type of tissue.

According to Bollag, the company used stem cells to create muscle tissue, and used a combination of plant protein and fats to round out the prototype. In the future, Bollag says the company intends to use stem cells to create the other parts of the bacon.

For Higher Steaks, creating the worlds first lab-grown bacon prototype is a big accomplishment. Dutch startup Meatable raised $10 million late last year as part of their effort to create a lab-grown pork, while New Age Meats debuted a lab-grown pork sausage prototype in 2018.

If youre excited to try out cultivated bacon, you may have to wait a few years. According to Bollag, lab-grown bacon and pork belly will take a while to get to market.

So I think in the next two to three years, youll start seeing it in the upper end, maybe in select restaurants, small quantities said Bollag. I think for it to be mass market, really price comparison and supermarket, youre looking more around five years.

You can see my full interview with Bollag talking about the development of their bacon and pork belly prototypes below.

The rest is here:
Higher Steaks Creates World's First Lab-Grown Bacon and Pork Belly - The Spoon

Zika: Research team use experimental drug that reduces replication of the virus and prevents microcephaly in mice – Outbreak News Today

By Stem Cell Treatment

An international group of researchers have discovered that inhibiting AHR (aryl hydrocarbon receptor), a protein with roles in regulating immunity, stem cell maintenance and cellular differentiation, enables the immune system to combat replication of zika virus in the organism far more effectively. In experiments performed at the University of So Paulos Biomedical Sciences Institute (ICB-USP) in Brazil, the antiviral therapy proved capable of preventing the development of microcephaly and other malformations in mouse fetuses whose mothers were infected while pregnant.

The study wassupported by FAPESP. An article describing the results waspublishedon July 20 in the journalNature Neuroscience.

In the experiments, we used an experimental drug that inhibits AHR and observed a decrease in replication of both zika virus and dengue virus. We now plan to test the effectiveness of the therapy against the novel coronavirus, saidJean Pierre Peron, a professor at ICB-USP and co-principal investigator for the project alongside Cybele Garcia, a virologist at the University of Buenos Aires in Argentina, and Francisco Quintana, a professor of neurology at Harvard Medical School in the United States.

The experimental model used in the study was the same as that used by Perons group in 2016 to prove a causal link between zika virus and microcephaly (read more atagencia.fapesp.br/23286/). On that occasion female mice of the SJL strain, which are much more susceptible to zika infection than other laboratory animals, were infected with the virus between the tenth and twelfth day of pregnancy. When the pups were born, the researchers found a significant reduction in cortical layer thickness, as well as alterations in the number and morphology of cortical and other brain cells. They also found that the virus replicated far more rapidly in placenta and in the pups brains than in other organs.

We repeated this experiment with a difference, Peron said. Shortly before we infected the pregnant females with zika, we began orally administering the AHR inhibitor. The treatment continued until the end of the gestational period. The pups had normal brains in terms of size and weight, and a far lower viral load than the non-treated control group. Viral load was almost undetectable in both the placenta and the central nervous system. In addition, histopathological analysis showed that there was no reduction in cortical layer thickness and that the number of nervous system cells killed by the virus was much smaller.

According to Peron, no adverse effects were observed in the mice treated with the AHR inhibitor, but before the treatment is tested in human volunteers the experiment must be replicated in monkeys.

The study took four years to be completed.Nagela ZanluquiandCarolina Polonio, both PhD candidates at ICB-USP with scholarships from FAPESP, also participated.

Inception

Quintanas laboratory at Harvard is one of the worlds leading centers in studies of the protein AHR. In an interview given toAgncia FAPESP, Quintana said his groupdiscoveredsome years ago that interferons, proteins produced by immune cells in the inflammatory response to infections, control the activation of AHR.

Because interferons are central to the antiviral immune response, we postulated together with Garcias group that AHR might be involved in the suppression of immunity against viruses. We designed anti-AHR therapies and developed nanoparticles and inhibitors for use in the experiments, Quintana said.

Tests performed in the laboratory and in animals confirmed that viruses activate AHR to suppress the hosts immune response. This may occur when a pathogen infects the liver, triggering release of the tryptophan metabolite kynurenine.

This metabolite activates AHR, which inhibits the expression of another protein called PML [promyelocytic leukemia protein, very important to the antiviral immune response] and thereby lets the virus replicate more freely in cells, Peron said.

At the University of Buenos Aires, Garcia led experiments with various cell lines including hepatocytes and neural progenitors, stem cells that have the capacity to differentiate into neuronal and glial cells.

We treated the cell lines with AHR agonist compounds [which magnify the action of the protein] and AHR antagonists [which inhibit it], Garcia toldAgncia FAPESP. In this manner we confirmed that negative modulation of this receptor inhibits replication of zika. In the same way we demonstrated that positive modulation boosts viral replication in cells.

Environmental factors

The impact of the 2015 zika epidemic was highly asymmetrical, Garcia said. In some regions and cities, the incidence of the congenital syndrome and microcephaly caused by the virus was much higher than in others. In her view this may be because of environmental factors favoring infection in the worst-hit areas or because their inhabitants were more susceptible. Both factors may also have contributed simultaneously to an intensification of zikas impact.

Coincidentally, AHR can be activated by environmental pollutants, and by certain diets or endogenous microbiota. Our next challenge is to rule out or confirm the existence of a link between AHR, polluted or socio-economically degraded environments and heightened virulence of zika, Garcia said.

The article AHR is a zika virus host factor and a candidate target for antiviral therapy can be read at:https://doi.org/10.1038/s41593-020-0664-0.

See more here:
Zika: Research team use experimental drug that reduces replication of the virus and prevents microcephaly in mice - Outbreak News Today

→←